PRACTICAL ONCOLOGY JOURNAL ›› 2015, Vol. 29 ›› Issue (1): 89-92.doi: 10.11904/j.issn.1002-3070.2015.01.020

• Review • Previous Articles     Next Articles

Drug treatment status and research progress on triple-negative breast cancer

LUO Jianing,GE Xiaofeng   

  1. Department of Radiotherapy,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,China
  • Received:2014-09-12 Online:2015-02-28 Published:2015-03-06

Abstract: Triple negative breast cancer(TNBC)is defined by the lack of expressions of the estrogen receptor(ER)、progesterone receptor(PR)and human epidermal growth factor receptor 2(HER-2).Although it is sensitive to radiation and chemotherapy,it lacks of appropriate targeted therapy and endocrine therapy.It performs characteristics of the strong invasion,high risk of recurrence and poor prognosis.So in recent years,triple negative breast cancer gets more and more attention from international oncology community.In-depth study of triple negative breast cancer will help the prevention,early diagnosis,judge the progress of the disease and improve prognosis.TNBC drug treatment and relevant research progress are reviewed in the present article.

CLC Number: